# US 2018/0021330 A1 · Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021330 A1
- Document ID: US20180021330A1
- Status: Published application
- Kind: A1
- Application number: 15/724,869
- Filed: 2017-10-04
- Published: 2018-01-25
- Earliest claimed: 2001-08-06
- Assignees: Purdue Pharma L.P.; The P.F. Laboratories, Inc.; Purdue Pharmaceuticals L.P.
- Applicants: Purdue Pharma L.P.; The P.F. Laboratories, Inc.; Purdue Pharmaceuticals L.P.
- Inventors: Benjamin Oshlack; Curtis Wright; Christopher Breder
- Web page: https://patentgrep.com/patent/US20180021330A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/205: {Polysaccharides, e.g. alginate, gums; Cyclodextrin}
- A61K 9/2081: {with microcapsules or coated microparticles according to A61K9/50}
- A61K 9/5078: {with drug-free core}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/36: Opioid-abuse
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.

## Claims

### Claim at position 1

1-32.

### Claim 33

A controlled release oral dosage form comprising:
a therapeutically effective amount of an opioid analgesic,
from about 10 ng to 275 mg of an opioid antagonist, and
particles consisting of a gelling agent, one or more pharmaceutically acceptable hydrophobic material(s) selected from the group consisting of cellulose polymers, acrylic polymers, polylactic acid, polyglycolic acid and a co-polymer of the polylactic acid and polyglycolic acid, and one or more additional pharmaceutically acceptable excipient(s),
wherein the gelling agent is releasable from said particles and a solubilized mixture having a viscosity unsuitable for injection is formed when the dosage form is crushed and dissolved in from about 1 to about 5 ml of water,
a weight ratio of the gelling agent to the opioid analgesic is from about 1:40 to about 40:1, and
the gelling agent is polyethylene oxide.

### Claim 34 (depends on 33)

The dosage form of claim 33, wherein the viscosity is at least 60 Cp.

### Claim 35 (depends on 33)

The dosage form of claim 33, wherein the viscosity is from 10 cP to 60 cP.

### Claim 36 (depends on 33)

The dosage form of claim 33, wherein the dosage form provides pain relief for at least about 12 hours when orally administered intact to a human patient.

### Claim 37 (depends on 33)

The dosage form of claim 33, wherein the opioid analgesic is selected from the group consisting of oxycodone, codeine, hydrocodone, hydromorphone, levorphanol, meperidine, morphine, pharmaceutically acceptable salts thereof, and mixtures thereof.

### Claim 38 (depends on 38)

The dosage form of claim 38, wherein the opioid analgesic is oxycodone or a pharmaceutically acceptable salt thereof.

### Claim 39 (depends on 33)

The oral dosage form of claim 33, wherein the opioid antagonist comprises naloxone or a pharmaceutically acceptable salt thereof.

### Claim 40

A controlled release oral dosage form comprising:
a therapeutically effective amount of an opioid analgesic selected from the group consisting of oxycodone, codeine, hydrocodone, hydromorphone, levorphanol, meperidine, morphine, pharmaceutically acceptable salts thereof, and mixtures thereof,
an opioid antagonist, and
particles consisting of a gelling agent, one or more pharmaceutically acceptable hydrophobic material(s) selected from the group consisting of cellulose polymers, acrylic polymers, polylactic acid, polyglycolic acid and a co-polymer of the polylactic acid and polyglycolic acid, and one or more additional pharmaceutically acceptable excipient(s),
wherein the gelling agent is releasable from said particles in an effective amount such that syringeability is hindered when the dosage form is crushed and dissolved in from about 1 to about 5 ml of water,
a weight ratio of the gelling agent to the opioid analgesic is from about 1:40 to about 40:1, and
the gelling agent is polyethylene oxide.

### Claim 41 (depends on 40)

The dosage form of claim 40, wherein the opioid analgesic is oxycodone or a pharmaceutically acceptable salt thereof.

### Claim 42 (depends on 40)

The dosage form of claim 40, wherein the opioid analgesic is hydrocodone or a pharmaceutically acceptable salt thereof.

### Claim 43 (depends on 40)

The dosage form of claim 40, wherein the opioid analgesic is morphine or a pharmaceutically acceptable salt thereof.

### Claim 44 (depends on 40)

The dosage form of claim 40, wherein the viscosity is at least 60 Cp.

### Claim 45 (depends on 40)

The dosage form of claim 40, wherein the opioid antagonist comprises naltrexone or a pharmaceutically acceptable salt thereof.

### Claim 46 (depends on 40)

The dosage form of claim 40, wherein the dosage form provides pain relief for at least about 12 hours when orally administered intact to a human patient.

### Claim 47 (depends on 46)

The dosage form of claim 46, wherein the dosage form provides pain relief for about 24 hours when orally administered intact to the human patient.

### Claim 48 (depends on 42)

The dosage form of claim 42, wherein the dosage form provides pain relief for at about 24 hours when orally administered intact to the human patient.

### Claim 49

A controlled release oral dosage form comprising:
a therapeutically effective amount of an opioid analgesic selected from the group consisting of oxycodone, codeine, hydrocodone, hydromorphone, levorphanol, meperidine, morphine, pharmaceutically acceptable salts thereof, and mixtures thereof,
an opioid antagonist, and
particles consisting of a gelling agent, one or more pharmaceutically acceptable hydrophobic material(s) selected from the group consisting of cellulose polymers, acrylic polymers, polylactic acid, polyglycolic acid and a co-polymer of the polylactic acid and polyglycolic acid, and one or more additional pharmaceutically acceptable excipient(s),
wherein the gelling agent is releasable from said particles in an effective amount such that the dosage form forms a gel that cannot be drawn into an insulin syringe without picking up pockets of air when the dosage form is crushed and dissolved in from about 1 to about 5 ml of water,
a weight ratio of the gelling agent to the opioid analgesic is from about 1:40 to about 40:1, and
the gelling agent is polyethylene oxide.
